NCT07609823招募中2 期
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Lacutoclax (LP-108) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.1 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2026年7月14日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 75
- 试验地点
- 1
研究概览
简要总结
The goal of this clinical trial is to evaluate the efficacy and safety of Lacutoclax, an oral selective BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Lacutoclax is a potent and selective BCL-2 inhibitor with relatively weaker inhibitory activity against BCL-XL and BCL-W. Preliminary clinical data have demonstrated promising efficacy and an acceptable safety profile in patients with CLL/SLL and other B-cell non-Hodgkin lymphomas (B-NHLs). This is an open-label, single-arm, multicenter Phase II study evaluating the efficacy and safety of oral Lacutoclax tablets in patients with relapsed or refractory CLL/SLL.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with confirmed R/R CLL/SLL according to the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria.
- •Patients who had previously received standard therapy, experienced disease progression following the most recent line of treatment (excluding intolerance), and had at least one indication for treatment prior to enrollment.
- •Have at least one measurable lesion.
- •Age ≥18 years, regardless of sex.
- •Eastern Cooperative Oncology Group (ECOG) performance status score ≤
- •Life expectancy ≥ 12 weeks.
- •Adequate coagulation function, liver and kidney function, bone marrow hematopoietic function.
- •Toxicities from prior anti-tumor therapy have recovered to Grade ≤1 according to NCI CTCAE v5.
- •Male patients and female patients of childbearing potential must agree to use effective contraception during the study and for 90 days after the last dose of Lacutoclax. Female patients of childbearing potential must have a negative pregnancy test before study treatment and must not be breastfeeding. Male patients must not donate sperm during the study and for 90 days after the last dose of Lacutoclax.
- •Participation is voluntary, requiring signed informed consent and compliance with the treatment regimen and visit schedule.
排除标准
- •Known hypersensitivity to Lacutoclax or any of its excipients.
- •Prior treatment with a BCL-2 family inhibitor.
- •History of or currently suspected Richter's syndrome.
- •Known or suspected central nervous system (CNS) involvement.
- •Prior allogeneic hematopoietic stem cell transplantation (allo-HSCT), or autologous hematopoietic stem cell transplantation (auto-HSCT) or chimeric antigen receptor T-cell (CAR-T) therapy within 90 days before the first dose of study treatment.
- •Received antitumor therapy, investigational agents, major surgery, severe trauma, or live attenuated vaccines within 4 weeks or 5 half-lives prior to the first dose of study treatment.
- •Received corticosteroids for antitumor purposes, herbal medicines for antitumor treatment, or localized radiotherapy within 14 days prior to the first dose of study treatment.
- •Use of moderate or strong CYP3A inhibitors within 7 days prior to the first dose of study treatment, or consumption of grapefruit, grapefruit juice, starfruit, or Seville oranges within 3 days prior to dosing.
- •Prior malignancy other than CLL/SLL within the past 2 years, except for curatively treated basal cell carcinoma, localized squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or other malignancies considered cured.
- •Major cardiovascular or cerebrovascular events within 6 months prior to the first dose of study treatment.
- •Presence of any severe and/or uncontrolled systemic disease.
- •Impaired cardiac function.
- •Any uncontrolled systemic infection.
- •Conditions that may impair oral drug administration or significantly affect absorption or pharmacokinetics of the study drug.
- •Unable to discontinue moderate or strong CYP3A inhibitors or inducers, or sensitive CYP2C8 substrates during the study period.
- •Primary autoimmune disease requiring immunosuppressive therapy.
- •Any other condition that, in the investigator's judgment, makes the patient unsuitable for study participation.
研究组 & 干预措施
Lacutoclax
Experimental
All participants will receive oral Lacutoclax tablets once daily with dose escalation to a target dose of 400 mg.
干预措施: Lacutoclax (Drug)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell LymphomaWMNCT07459608Henan Cancer Hospital75
已完成
2 期
To evaluate the Efficacy and Safety of study product i.e., LYCO3 in Male Subjects who Suffering from Erectile DysfunctionCTRI/2024/07/071171Nutragen Pharma Pvt. Ltd.20
招募中
3 期
A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb SpasticityNCT07478822Chongqing Claruvis Pharmaceutical Co., Ltd.300
招募中
3 期
Study to evaluate efficacy and safety of Human normal immunoglobulin given in veins in patients with Immune thrombocytopenia (Low levels of the cells that help blood clot)CTRI/2025/08/093411Bharat Serums and Vaccines Ltd30
招募中
1 期
U69-CART-Cells For R/R T-ALLNCT07350863The First Affiliated Hospital of Soochow University12